Advertisement
YOU ARE HERE: LAT HomeCollectionsFda
IN THE NEWS

Fda

NEWS
March 21, 2013 | By Monte Morin
La Preferida Inc. is voluntarily recalling 56,808 29-ounce cans of La Preferida Whole Pinto Beans, the U.S. Food and Drug Administration announced Thursday. "The manufacturer's preliminary inspection indicates 420 cans may not have been fully processed, which could result in product contamination by spoilage organisms or by pathogens, which could lead to illness if consumed," the FDA said. "To date, there have been no reported injuries or adverse events associated with the consumption of this product.
Advertisement
NEWS
July 13, 2011 | Christine Mai Duc
WASHINGTON – Following a spike in reported complications, the Food and Drug Administration released an updated advisory Wednesday about a surgical mesh implanted in women to strengthen vaginal tissue that can become weakened, especially after childbirth. In its report, the FDA says a review of industry literature and the adverse event reports has shown little evidence that the device, which is implanted vaginally or abdominally, improves pelvic organ prolapse, where a woman's uterus, bladder, or rectum can slip out of place.
NEWS
June 23, 2011 | By Marissa Cevallos, HealthKey / For the Booster Shots blog
The Food and Drug Administration is essentially telling U.S. consumers worried about silicone breast implants: “Told you so.” But in releasing new research backing up its 2006 decision to allow the implants back onto the market, the agency also reminds women, in a way, that they have only two choices — silicone or saline. So let’s take a look at those options. Until 2006, silicone implants had been under a 14-year ban by the FDA because of concerns that leaks or ruptures could increase the risk of certain diseases, including breast cancer and connective tissue diseases.
NEWS
August 2, 2011 | By Andrew Seidman
A coalition of nearly 30 organizations in the animal agriculture industry sent a letter to the heads of the House and Senate on Tuesday, asking lawmakers not to intervene as the Food and Drug Administration considers whether to approve genetically engineered salmon as food. The letter comes more than a month after the House approved an amendment, by voice acclamation, to an appropriations bill that would strip the FDA of funding to study the salmon. On July 15, members of the House and Senate sent letters to the FDA asking it to abandon its consideration of modified salmon as food, and threatened to propose legislation to bar further study of the fish if the agency does not comply.
BUSINESS
October 30, 2013 | By David Pierson
About 12% of spices imported into the U.S. each year is contaminated with insects, animal excrement, rodent hair and even rubber bands, according to a Food and Drug Administration draft report released Wednesday. The study was conducted in response to recent cases of salmonella found in imported spices. It looked at ways to reduce the rates of human illness caused by contamination in the seasonings. “Nearly all of the insects found in spice samples were stored product pests, indicating inadequate packing or storage conditions.
BUSINESS
December 13, 2011 | Reuters
U.S. health regulators sent warning letters to eight California surgical centers and a marketing firm for providing misleading information while advertising Allergan Inc.'s Lap-Band, a device used to treat obesity. The U.S. Food and Drug Administration said billboards and advertising inserts used by the surgical centers and the marketing firm 1-800-GET-THIN fail to provide required risk information, including warnings, precautions and possible side effects. The FDA issued warning letters to Bakersfield Surgery Institute Inc, Beverly Hills Surgery Center, Palmdale Ambulatory Center, Valley Surgical Center, Top Surgeons, Valencia Ambulatory Center, Cosmopolitan Plastic & Reconstructive Surgery and San Diego Ambulatory Center.
NEWS
March 2, 2011 | By Julie Deardorff, Chicago Tribune
The Food and Drug Administration plans to remove some unapproved prescription cough, cold and allergy medicines now sitting on store shelves, the agency announced Wednesday. The products, which may be inappropriately labeled for use by infants and young children, could pose an unnecessary risk because they haven't been tested for safety and efficacy, the FDA said. Some may have risky ingredients, and others -- marketed as 'timed release' -- may release active ingredients too slowly, too quickly or inconsistently.
BUSINESS
February 2, 2012 | By Matt Stevens
Trace levels of the fungicide carbendazim were discovered in domestic orange juice samples, the Food and Drug Administration reported Thursday. But the FDA said the levels pose no safety risk, and the orange juice will not be recalled. FDA spokeswoman Siobhan DeLancey said that most of the samples taken were from concentrated products that will be blended down into the orange juice consumers drink, so the low levels of carbendazim will almost disappear. “We didn't have any evidence to indicate that the product on the market was any safety problem at all,” DeLancey said.
NEWS
April 9, 2013 | By Melissa Healy
The Food and Drug Administration on Monday approved a drug to treat the severe nausea and vomiting that some women experience during early pregnancy. The Canadian-made medication will be marketed as Diclegis. It is the only prescription medication approved for pregnant women experiencing "morning sickness" that does not go away with a bland diet of small meals that are low in fat. Diclegis was once known and marketed in the United States as Bendectin and taken by as many as one in 10 pregnant women.
NEWS
September 14, 2010
The Food and Drug Administration released information Tuesday suggesting it's unimpressed by a weight-loss medication under development by Arena Pharmaceuticals Inc. and casting doubt on the drug's eventual approval. An FDA advisory committee is scheduled to meet Thursday and vote on whether to recommend approval of the drug, lorcaserin. But in documents released Tuesday in advance of the meeting, the FDA noted that studies on lorcaserin showed the average weight loss while taking the drug was not significantly different than the average weight loss among people taking a placebo.
Los Angeles Times Articles
|